DAS ARIJIT (IN)
CHENNURU RAMANAIAH (IN)
LAKKIREDDY PULLAREDDY (IN)
DEVARAPALLI RAMESH (IN)
MUDDA RAMESH REDDY (IN)
WO2021046303A1 | 2021-03-11 |
US20210017151A1 | 2021-01-21 |
We claim, 1. A co-crystal of niraparib tosylate and L-proline. 2. The co-crystal of claim 1, wherein the molar ratio of niraparib tosylate to L-proline is between 2:1 to 1:2. 3. The co-crystal of claim 1, wherein the molar ratio of niraparib tosylate to L-proline is 1:1. 4. The co-crystal of claim 1, wherein at least about 50% of the co-crystal is in the crystalline form. 5. The co-crystal of claim 4, characterized by XRPD diffractogram with characteristics peaks at 9.08, 14.20, 16.90, 18.17 and 20.1 ± 0.2˚2θ. 6. The co-crystal of claim 4, further characterized by XRPD diffractogram as depicted in Figure 11 and Figure 12. 7. The co-crystal of claim 4, characterized by a DSC thermogram having an endothermic peak with onset at around 215.41±5°C; and a peak maximum at around 217.40 ±5°C. 8. The co-crystal of claim 4, further characterized by having a DSC thermogram as shown in Figure 13. 9. The co-crystal of claim 4, further characterized by data selected from the group consisting of: the group consisting of: an X-ray powder diffraction pattern having peaks at about : 9.08, 14.20, 16.90, 18.17 and 20.1 ± 0.2 °2θ; a XRPD diffractogram as depicted in Figure 11; a XRPD diffractogram as depicted in Figure 12; a DSC thermogram having a first endothermic peak in the range of about 215.41±5°C; a peak maximum at around 217.40 ±5°C; a DSC pattern as depicted in Figure 13; and combinations thereof. 10. A process for preparing co-crystal of niraparib tosylate and L-proline of claim 4, the process comprising, f. stirring L-proline in a first organic solvent selected from the group comprising of C1-C5 alcohol or a mixture of C1-C5 alcohols thereof; g. mixing Niraparib tosylate; h. heating the mixture for sufficient time; i. isolating the co-crystal of Niraparib tosylate with L-proline; and j. drying. 11. The process of claim 10, wherein the first organic solvent C1-C5 alcohol, is preferably selected from the group comprising of methanol, ethanol, isopropanol, n-propanol, n-butanol, isobutanol, t-butanol, amyl alcohol and the like. 12. A process for preparing co-crystal of niraparib tosylate and L-proline of claim 4, the process comprising, a. stirring Niraparib tosylate and L-proline in a polar aprotic solvent or mixture thereof; b. heating the mixture for sufficient time; c. isolating the co-crystal of Niraparib tosylate with L-proline; and d. drying. 13. The process of claim 12, wherein the polar aprotic solvent is selected from the group comprising of N, N- dimethylacetamide (DMAC), dimethylformamide (DMF), dimethylsulfoxide (DMSO), N- methylpyrrolidone (NMP), tetrahydrofuran (THF), sulfolane, diglyme, 1,4-dioxane and the like; nitrile solvent such as acetonitrile, propionitrile, butyronitrile and the like. 14. A pharmaceutical composition in the form of a tablets, powders, capsule, liquid suspension or an injectable and the like, comprising the co-crystal of Niraparib tosylate with L-proline of claim 1 and a pharmaceutically acceptable excipient. 15. A pharmaceutical composition of claim 14, wherein the co-crystal of Niraparib tosylate with L-proline is formulated into tablets, film-coated tablets, sugar coated tablets, pills, dragees, capsules, soft gelatin capsules, hard gelatin capsules, troches, aqueous suspensions or solutions, dispersions, injectables and other pharmaceutical forms. 16. A method of prevention and/or treatment of treating epithelial ovarian, fallopian tube, or primary peritoneal cancer and combinations thereof comprising administering to a patient in need thereof a therapeutically effective amount of the co-crystal of Niraparib tosylate with L-proline of claim 1. 17. Use of co-crystal of Niraparib tosylate with L-proline of claim 1, in the manufacture of a medicament for prevention and/or treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer and combinations thereof. 18. Use of co-crystal of Niraparib tosylate with L-proline of claim 1, in the prevention and/or treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer and combinations thereof. |
Advantageously, in a second aspect, a given percentage of the co-crystal is in crystalline form, which is herein and in the claims designated as “Form C1”. For example, in various embodiments at least about 50% of the co-crystal is in crystalline form. In other embodiments, at least about 80 or at least about 90% of the co-crystal is in crystalline form. In an embodiment, the co-crystal of Niraparib tosylate with L-proline can be characterized as having peaks in X-ray powder diffraction patterns obtained therefrom. For example, co-crystal can be characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2-theta diffraction angles: 7.63, 8.96, 14.07, 16.69 and 25.96 ±0.2˚2θ. The XRPD diffractogram may comprise further peaks at 14.79, 18.00, 18.77, 23.83 and 27.56 ±0.2˚2θ. In another embodiment, the co-crystal of Niraparib tosylate with L-proline is characterized by having an XRD pattern as shown in Figure 1. The crystalline Form C1 of the co-crystal of Niraparib tosylate with L-proline is characterized as having a DSC spectrum exhibiting an endothermic peak with onset at around 215.19±5°C; a peak maximum at around 216.74 ±5°C and an enthalpy 81.98 j/g. In an embodiment, crystalline Form C1 of Niraparib tosylate with L-proline may be characterized by having a DSC spectrum as shown in Figure 2. In an embodiment, crystalline Form C1 of the co-crystal of Niraparib tosylate with L-proline may also be characterized by having a thermogravimetric analysis as shown in Figure 3. TGA data indicated a weight loss of 0.09% at temperatures up to 120°C. The TGA analysis indicates the crystalline Form C1 of Niraparib tosylate with L- proline is the anhydrous form. The crystalline Form C1 of Niraparib tosylate with L-proline may be further characterized by data selected from the group consisting of: an X-ray powder diffraction pattern having peaks at about 7.63, 8.96, 14.07, 16.69 and 25.96 ± 0.2 °2θ; an X-ray powder diffraction pattern having peaks at about 14.79, 18.00, 18.77, 23.83 and 27.56 ± 0.2 °2θ; a XRPD diffractogram as depicted in Figure 1; a DSC thermogram having a first endothermic peak in the range of about 215.19±5°C °C, a peak maximum at around 216.74 ±5°C and an enthalpy 81.98 j/g; a DSC pattern as depicted in Figure 2; a TGA pattern as depicted in Figure 3; and combinations thereof. In an embodiment, Oak Ridge Thermal Ellipsoid Plot (ORTEP) of the co- crystal of Niraparib tosylate - L-Proline was drawn with Mercury. The ellipsoids are at 50% probability. In an embodiment, an ORTEP drawing of co-crystal of Niraparib tosylate - L- Proline is shown in Figure 7. A summary of the crystal data and crystallographic data collection parameters are provided in Table 1 below. Table 1
The molecule observed in the asymmetric unit of the single crystal structure is consistent with the Formula III molecular structure. The asymmetric unit shown in Figure 7 contains co-crystal of Niraparib tosylate - L-Proline in the 1 : 1 molar ratio. Indicative Stability
The stability of Niraparib tosylate : L-Proline co-crystal (Form-C1) prepared as per the present disclosure was studied by storing the samples at 2-8°C, 25°C/ 60% RH; and 40°C/ 75% RH storage conditions upto 6 months. The samples were analysed for PXRD, HPLC purity and water content at predetermined time intervals of 1M, 2M, 3M and 6M. The stability data collected after 6 months of storage are tabulated below in Table 2.
Table 2. Indicative Stability of Niraparib tosylate : L-Proline co-crystal (Form-C1)
* Samples were exposed to atmosphere and odd water content result observed, hence water content was not analysed.
The data indicates that there is no significant change with respect to PXRD, HPLC purity and water content in all the storage conditions up to 6 months.
According to a third aspect of the present invention, there is provided a process for preparing co-crystal of Niraparib tosylate with L-proline, the process comprising, a. dissolving Niraparib tosylate and L-proline in a first organic solvent selected from the group comprising of C 1 -C 5 alcohol or a mixture of C 1 - C 5 alcohols thereof; b. removing the solvent under reduced pressure to obtain a residue; c. stirring the residue for sufficient time in a second organic solvent selected from polar aprotic solvent, ketone, nitriles, ethers, esters, hydrocarbons and the like; d. isolating the co-crystal of Niraparib tosylate with L-proline; and e. drying.
Niraparib tosylate used for the above process, as well as for the following processes, may be in any polymorphic form or in a mixture of any polymorphic forms such as hydrated, solvated, non-solvated or mixture of hydrated, solvated or non-solvated forms thereof. The Niraparib tosylate used in the processes of the present invention can be obtained by any method known in the art, such as the one described in the US 8,436,185 B2. The first organic solvent C 1 -C 5 alcohol, is preferably selected from the group comprising of methanol, ethanol, isopropanol, n-propanol, n-butanol, isobutanol, t-butanol, amyl alcohol and the like. Preferably, first organic solvent is methanol. The second organic solvent is preferably selected from the group comprising of polar aprotic solvent such as N,N- dimethylacetamide (DMAC), dimethylformamide (DMF), dimethylsulfoxide (DMSO), N- methylpyrrolidone (NMP), tetrahydrofuran (THF), sulfolane, diglyme, 1,4- dioxane and the like; ether solvent such as methyl t-butyl ether, diisoproyl ether, tetrahydrofuran (THF) and the like; ester solvent such as methyl acetate, ethyl acetate, isopropyl acetate and the like; nitrile solvent such as acetonitrile, propionitrile and the like; ketone solvent such as acetone, methyl isobutyl ketone and the like; halogenated solvent such as dichloromethane, dichloroethane, chloroform and the like; C 6 -C 10 substituted aromatic hydrocarbons, and C 1 -C 5 halogenated hydrocarbons; water and mixtures thereof. Preferably, organic solvent is selected from but not limited to nitrile solvent. Preferably, dissolution step is done at about 40°C to about 80°C, more preferably at about 50°C to about 70°C to obtain a solution. Typically, following the heating step, the evaporation is done under reduced pressure. Preferably, after addition of a second organic solvent, the process further comprises a stirring step. Preferably, the stirring is for about 1 hour to about 24 hours, more preferably for about 2 hours to about 20 hours. Preferably, the stirring is done at about 50°C to about 80°C. Preferably, the obtained solid form is isolated. Preferably, the isolation is done by centrifugation. The drying may be done in a vacuum oven at a temperature of about 25°C to about 60°C, more preferably at about 30°C to about 50°C, for about 1 hour to about 10 hours, more preferably for about 2 hours to about 8 hours. The co-crystal of Niraparib tosylate with L-proline (Form-C1), obtained as per the present invention is substantially free from other forms of Niraparib tosylate. "Substantially free" from other forms of Niraparib tosylate shall be understood to mean that the co-crystals of Niraparib tosylate contain less than 10%, preferably less than 5%, of any other forms of Niraparib tosylate and less than 1% of other impurities. Advantageously, in a fourth aspect, a given percentage of the co-crystal is in crystalline form, which is herein and in the claims designated as “Form C2”. For example, in various embodiments at least about 50% of the co-crystal is in crystalline form. In other embodiments, at least about 80 or at least about 90% of the co-crystal is in crystalline form. In an embodiment, the co-crystal of Niraparib tosylate with L-proline can be characterized as having peaks in X-ray powder diffraction patterns obtained therefrom. For example, co-crystal can be characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2-theta diffraction angles: 9.08, 14.20, 16.90, 18.17 and 20.1 ±0.2˚2θ. In another embodiment, the co-crystal of Niraparib tosylate with L-proline is characterized by having an XRD pattern as shown in Figure 11 and Figure 12. The crystalline Form C2 of the co-crystal of Niraparib tosylate with L-proline is characterized as having a DSC spectrum exhibiting an endothermic peak with onset at around 215.41±5°C; a peak maximum at around 217.40 ±5°C and an enthalpy 95.737 j/g. In an embodiment, crystalline Form C2 of Niraparib tosylate with L-proline may be characterized by having a DSC spectrum as shown in Figure 13. The crystalline Form C2 of Niraparib tosylate with L-proline may be further characterized by data selected from the group consisting of: an X-ray powder diffraction pattern having peaks at about : 9.08, 14.20, 16.90, 18.17 and 20.1 ± 0.2 °2θ; a XRPD diffractogram as depicted in Figure 11; a XRPD diffractogram as depicted in Figure 12; a DSC thermogram having a first endothermic peak in the range of about 215.41±5°C; a peak maximum at around 217.40 ±5°C and an enthalpy 95.737 j/g; a DSC pattern as depicted in Figure 13; and combinations thereof. According to a fifth aspect of the present invention, there is provided a process for preparing co-crystal of Niraparib tosylate with L-proline, the process comprising, a. stirring L-proline in a first organic solvent selected from the group comprising of C 1 -C 5 alcohol or a mixture of C 1 -C 5 alcohols thereof; b. mixing Niraparib tosylate; c. heating the mixture for sufficient time; d. isolating the co-crystal of Niraparib tosylate with L-proline; and e. drying. The first organic solvent C 1 -C 5 alcohol, is preferably selected from the group comprising of methanol, ethanol, isopropanol, n-propanol, n-butanol, isobutanol, t-butanol, amyl alcohol and the like. Preferably, first organic solvent is isopropanol. Preferably, L-Proline is stirred in alcohol at about 25°C to about 70°C, more preferably at about 40°C to about 60°C. Preferably, after mixing Niraparib tosylate, the process further comprises a heating step. Preferably, the heating is done at about 50°C to about 90°C, more preferably at about 60°C to about 85°C, for about 1 hour to about 20 hours, more preferably for about 2 hours to about 10 hours. Typically, following the heating step, the process further comprises a cooling step. Preferably, the cooling is done at about 20°C to about 30°C, for about 30 minutes to about 5 hours, more preferably for about 1 hour to about 3 hours. Preferably, the obtained solid form is isolated. Preferably, the isolation is done by centrifugation. The drying may be done in a vacuum oven at a temperature of about 25°C to about 60°C, more preferably at about 30°C to about 50°C, for about 1 hour to about 10 hours, more preferably for about 2 hours to about 8 hours. Alternatively, Niraparib tosylate : L-Proline co-crystal (Form-C2) may be obtained by the process comprising, a. stirring Niraparib tosylate and L-proline in a polar aprotic solvent or mixture thereof; b. heating the mixture for sufficient time; c. isolating the co-crystal of Niraparib tosylate with L-proline; and d. drying. Preferably polar aprotic solvent is selected from the group comprising of N,N- dimethylacetamide (DMAC), dimethylformamide (DMF), dimethylsulfoxide (DMSO), N-methylpyrrolidone (NMP), tetrahydrofuran (THF), sulfolane, diglyme, 1,4-dioxane and the like; nitrile solvent such as acetonitrile, propionitrile, butyronitrile and the like. Preferably, polar aprotic solvent is acetonitrile. Preferably, after mixing heating is done for about 1 hour to about 20 hours, more preferably for about 2 hours to about 10 hours. Preferably, the heating is done at about 50°C to about 90°C, more preferably at about 60°C to about 80°C. Typically, following the heating step, the process further comprises a cooling step. Preferably, the cooling is done at about 30°C to about 40°C. Preferably, the obtained solid form is isolated. Preferably, the isolation is done by centrifugation. The drying may be done in a vacuum oven at a temperature of about 25°C to about 60°C, more preferably at about 30°C to about 50°C, for about 2 hour to about 10 hours, more preferably for about 3 hours to about 6 hours. The co-crystal of Niraparib tosylate with L-proline (Form-C2), obtained as per the present invention is substantially free from other forms of Niraparib tosylate. "Substantially free" from other forms of Niraparib tosylate shall be understood to mean that the co-crystals of Niraparib tosylate contain less than 10%, preferably less than 5%, of any other forms of Niraparib tosylate and less than 1% of other impurities. In a sixth aspect, the present invention provides a novel co-crystal of Niraparib tosylate with oxalic acid. The co-crystal may be in the form of a derivative thereof. The derivative may be a pharmaceutically acceptable solvate, hydrate, tautomer, anhydrate, complex, polymorph or combination thereof. In one embodiment, co-crystal is mono oxalic acid co-crystal. The mono oxalic acid co-crystal can, in certain embodiments, be in hydrated or solvated form. In another embodiment, co-crystal is di oxalic acid co-crystal. The di oxalic acid co-crystal can, in certain embodiments, be in hydrated or solvated form. Preferably, the co-crystals comprises Niraparib tosylate and oxalic acid within the same crystalline phase in a molar ratio ranging from 2 :1 to 1:2. More preferably the molar ratio is 1 :1. Accordingly, the co-crystal of Niraparib tosylate with oxalic acid is characterized by having the chemical structure as depicted in Formula (IV). Advantageously, in a seventh aspect , a given percentage of the co-crystal is in crystalline form, which is herein and in the claims designated as “Form C1”. For example, in various embodiments at least about 50% of the co-crystal is in crystalline form. In other embodiments, at least about 80 or at least about 90% of the co-crystal is in crystalline form. In an embodiment, the co-crystal of Niraparib tosylate with oxalic acid can be characterized as having peaks in X-ray powder diffraction patterns obtained therefrom. For example, co-crystal can be characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2-theta diffraction angles: 5.94, 8.20, 11.78 and 16.78 ±0.2˚2θ. The XRPD diffractogram may comprise further peaks at 12.77, 15.63, 17.77, 20.74 and 22.20 ±0.2˚2θ. In another embodiment, the co-crystal of Niraparib tosylate with oxalic acid is characterized by having an XRD pattern as shown in Figure 4. The crystalline Form C1 of the co-crystal of Niraparib tosylate with oxalic acid is characterized as having a DSC spectrum exhibiting an endothermic peak with onset at around 184.96 ±5°C; a peak maximum at around 186.93 ±5°C and an enthalpy 67.67 j/g. In an embodiment, crystalline Form C1 of Niraparib tosylate with oxalic acid may be characterized by having a DSC spectrum as shown in Figure 5. In an embodiment, crystalline Form C1 of the co-crystal of Niraparib tosylate with oxalic acid may also be characterized by having a thermogravimetric analysis as shown in Figure 6. TGA data indicated a weight loss of 0.11% at temperatures up to 120°C. The TGA analysis indicates the crystalline Form C1 of Niraparib tosylate with oxalic acid is the anhydrous form. The crystalline Form C1 of Niraparib tosylate with oxalic acid may be further characterized by data selected from the group consisting of: an X-ray powder diffraction pattern having peaks at about 5.94, 8.20, 11.78 and 16.78 ± 0.2 °2θ; an X-ray powder diffraction pattern having peaks at about 12.77, 15.63, 17.77, 20.74 and 22.20 ± 0.2 °2θ; a XRPD diffractogram as depicted in Figure 4; a DSC thermogram having a first endothermic peak in the range of about 184.96±5°C °C, a peak maximum at around 186.93 ±5°C and an enthalpy 67.67 j/g; a DSC pattern as depicted in Figure 5; a TGA pattern as depicted in Figure 6; and combinations thereof. According to eighth aspect of the present invention, there is provided a process for preparing co-crystal of Niraparib tosylate with oxalic acid, the process comprising, a. Mixing Niraparib tosylate and oxalic acid in a suitable organic solvent selected from the group comprising of polar aprotic solvent, ketone, nitriles, ethers, esters, hydrocarbons and the like thereof; b. stirring for sufficient time; c. isolating the co-crystal of Niraparib tosylate with oxalic acid; and d. drying. The organic solvent is preferably selected from the group comprising of polar aprotic solvent such as N,N- dimethylacetamide (DME), dimethylformamide (DMF), dimethylsulfoxide (DMSO), N-methylpyrrolidone (NMP), tetrahydrofuran (THF), sulfolane, diglyme, 1,4-dioxane and the like; ether solvent such as methyl /-butyl ether, diisopropyl ether, tetrahydrofuran (THF) and the like; ester solvent such as methyl acetate, ethyl acetate, isopropyl acetate and the like; nitrile solvent such as acetonitrile, propionitrile and the like; ketone solvent such as acetone, methyl isobutyl ketone and the like; halogenated solvent such as dichloromethane, dichloroethane, chloroform and the like; C6-C10 substituted aromatic hydrocarbons, and C1-C5 halogenated hydrocarbons; water and mixtures thereof. Preferably, organic solvent is selected from but not limited to nitrile such as acetonitrile, propionitrile and the like. Preferably, mixing is done at about 20°C to about 30°C. Preferably, the process further comprises a stirring step. Preferably, the stirring is for about 1 hour to about 10 hours, more preferably for about 2 hours to about 5 hours. Preferably, the stirring is done at about 30°C to about 90°C; more preferably at about 50°C to about 80°C. Preferably, the process further comprises a cooling step. Preferably, cooling is done at about 25°C to about 30°C. Preferably, the obtained solid form is isolated. Preferably, the isolation is done by centrifugation. The drying may be done in a vacuum oven at a temperature of about 25°C to about 60°C, more preferably at about 30°C to about 40°C, for about 1 hour to about 10 hours, more preferably for about 2 hours to about 5 hours. The co-crystal of Niraparib tosylate with oxalic acid, obtained per the present invention is substantially free from other forms of Niraparib tosylate. "Substantially free" from other forms of Niraparib tosylate shall be understood to mean that the co-crystals of Niraparib tosylate contain less than 10%, preferably less than 5%, of any other forms of Niraparib tosylate and less than 1% of other impurities. The present invention provides a pharmaceutical composition comprising therapeutically effective amount of co crystals of Niraparib tosylate prepared by the processes of the present invention. The pharmaceutical composition comprising a therapeutically effective amount of Niraparib tosylate with any one of the co-crystal former as mentioned above along with one or more suitable pharmaceutically acceptable carriers/excipients. Further, the pharmaceutical composition of the invention may be any pharmaceutical form which contains the co-crystals of the invention. The pharmaceutical composition may be solid form such as tablets, powders, capsule, liquid suspension or an injectable composition along with any suitable carrier well known in the prior art. The dosage forms can also be prepared as sustained, controlled, modified and immediate release dosage forms. The invention relates to administering 'an effective amount' of the 'composition of invention' to the subject suffering from cancer. Accordingly, Niraparib tosylate co-crystals and the pharmaceutical composition containing them may be administered using any amount, any form of pharmaceutical composition via any route of administration effective for the treatment of cancer. The invention further discloses use of the "composition of the invention" in preparing the medicament intended to treat cancer. The invention will now be further described by the following examples, which are illustrative rather than limiting. Examples Example 1 Process to prepare Niraparib tosylate : L-Proline co-crystal (Form-C1): Niraparib tosylate (3.0 g) and L-proline (0.693 g) were dissolved in 27 volumes of methanol at 55-60°C. The solution was concentrated in a rotavapor at 55-60°C to get the residue. Charged 10 volumes of acetonitrile into the above residue and stirred for 2-3 hours at 70-75°C. The solids were isolated by filtration and dried at 45-50°C for 3-4 hours to yield the title compound. H-NMR reveals a molar ratio of Niraparib tosylate to L-proline of about 1:1. The crystallinity was confirmed by XRD, DSC and TGA and identified as Form C1 as depicted in Figures 1 to 3. Example 2 Process to prepare Niraparib tosylate : Oxalic acid co-crystal (Form-C1): Niraparib tosylate (3 g) and oxalic acid (1.48 g) were mixed with 15 volumes of acetonitrile. The contents were stirred at 70-75°C for 2-3 hours. The solids were cooled to RT and isolated by filtration and dried under vacuum to yield the title compound. The crystallinity was confirmed by XRD, DSC and TGA and identified as Form C1 as depicted in Figures 4 to 6. Example 3 Determination of the solubility of Niraparib tosylate : L-Proline co- crystal (Form-C1) in comparison to Niraparib tosylate monohydrate (Form I ) in buffered solutions (Solubility as a Function of pH) The aqueous solubility of Niraparib tosylate : L-Proline co-crystal (Form-C1) was compared with Niraparib tosylate monohydrate (Form I). The solubility of Form C1 of the invention was determined at pH 1.2 (Gastric Buffer), pH 4.5 (Acetate Buffer) and pH 6.8 (Intestinal Buffer), by suspending 0.3 g of Form- C1 and Form I in 30 mL of corresponding aqueous solution. The samples were allowed to equilibrate at ambient temperature for at least 24 hours for pH 1.2, 4.5 and 6.8 Buffers. The supernatant was filtered and used for the solubility determination by UV-VIS spectroscopy. The solid residue was analyzed by XRPD. The solubility data obtained are shown in Tables 3 to 5. The data and Figures 8-10 indicated that the solubility is pH and temperature dependent. Table 3 pH solubility data at pH 1.2
Table 4 pH solubility data at pH 4.5
Table 5 pH solubility data at pH 6.8 On the other side Niraparib tosylate : L-Proline co-crystal (Form-C1) is having comparable solubility with Niraparib tosylate monohydrate (Form I ) in all the above studied pH buffers. Example 4 Process to prepare Niraparib tosylate : L-Proline co-crystal (Form-C2): Niraparib tosylate (5.0 g) and L-proline (1.137 g) were stirred in 30 volumes of acetonitrile at reflux temperature for 4-5 hours. The solids were isolated by filtration and dried at 50-60°C for 3-4 hours to yield the title compound. H-NMR reveals a molar ratio of Niraparib tosylate to L-proline of about 1:1. The crystallinity was confirmed by XRD, and identified as Form C2 as depicted in Figure 11. Example 5 Process to prepare Niraparib tosylate : L-Proline co-crystal (Form-C2): Niraparib tosylate (5.0 g) was added in a mixture of L-proline (1.4 g) and IPA (100 ml) at 50°C. The contents were heated to 70-75°C for 6 hours. The contents were cooled to 25-30°C and stirred further at 25-30°C for 1 hour. The solids were isolated by filtration and dried at 45-50°C for 3-4 hours to yield the title compound. Water content :0.3% H-NMR reveals a molar ratio of Niraparib tosylate to L-proline of about 1:1. The crystallinity was confirmed by XRD, DSC and identified as Form C2 as depicted in Figures 12 and 13.